Rituximab Twice Weekly for Refractory Thrombotic Thrombocytopenic Purpura in a Critically Ill Patient with Acute Respiratory Distress Syndrome

Autor:	Bahjat Azrieh, Arwa Alsaud, Khaldun Obeidat, Amr Ashour, Seham Elebbi, Shehab F. Mohamed, Mohamed Adel Abdelaty, Abdelraouf Akkari, Abdurrahman Ali Elbuzidi, Mohamed A. Yassin
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	thrombotic thrombocytopenic purpura thrombocytopenia platelet disorder refractory disease relapse rituximab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Case Reports in Oncology, Vol 13, Iss 1, Pp 153-157 (2020)
Druh dokumentu:	article
ISSN:	1662-6575
DOI:	10.1159/000505236
Popis:	Thrombotic thrombocytopenic purpura (TTP) is a rare, serious, life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and hypercoagulability. The etiology is a deficiency of ADAMTS13 which is usually caused by acquired antibodies. Plasma exchange and steroids is the standard of care in the treatment of TTP. However, there are refractory cases of TTP which require further management. Rituximab appears to be a safe and effective therapy for refractory and relapsing TTP. Here we report a challenging case of TTP that responded to treatment with rituximab twice weekly. According to our knowledge, rituximab twice weekly has never been used for TTP before.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/eda8153d05a94d0d9d279ec01a154731 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.